Scribe Therapeutics (SCTX) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($400.8 million vs $257.4 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SCTX | UPB |
|---|---|---|
| Share price | $21.17 | $4.70 |
| Market cap | $400.78M | $257.42M |
| 1-day change | +10.09% | +3.30% |
| YTD return | — | -83.24% |
| 1-year return | — | -75.95% |
| EPS (TTM) | $-3.84 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.60 | $33.68 |
| 52-week low | $13.50 | $4.37 |
| Distance from 52-week high | -46.54% | -86.05% |
| Analyst consensus | none | none |
| Avg. price target upside | +169.25% | +562.55% |
| Average volume | 357.40K | 647.42K |
| Shares outstanding | 18.93M | 54.77M |
| Employees | 82 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
SCTX vs UPB FAQ
Which is bigger, Scribe Therapeutics or Upstream Bio?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $400.78M compared with $257.42M for Upstream Bio (UPB).
Are Scribe Therapeutics and Upstream Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Scribe Therapeutics and Biotechnology: Pharmaceutical Preparations for Upstream Bio.